Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC

LUND, SE / ACCESS Newswire / June 11, 2026 / Cantargia AB (Publ) (STO:CANTA) today announced a KOL Call to be hosted in collaboration with H.C. Wainwright with leading subject matter experts Drs. Peter Joel Hosein and Jashodeep Datta on the subject of IL1RAP as a Therapeutic Target in Pancreatic Cancer: The Case for Nadunolimab, on June 22, 2026.

The KOL Call will be facilitated by Dr. Sara Nik, Vice President Equity Research at H.C. Wainwright, with the purpose of discussing IL1RAP as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC) and the emerging clinical role of nadunolimab (CAN04), Cantargia's anti-IL1RAP antibody. Despite decades of incremental progress, PDAC remains one of the most treatment-refractory malignancies. However, the PDAC treatment landscape is undergoing a meaningful inflection with RAS pathway targeting as a therapeutic priority. In parallel, the IL-1/IL1RAP axis has emerged as a critical mediator of the immunosuppressive and pro-tumorigenic PDAC microenvironment, representing a mechanistically distinct and potentially complementary approach. Against this evolving backdrop, we believe this KOL call presents a timely opportunity to explore the biology of IL1RAP in PDAC, discuss how nadunolimab may complement emerging RAS-directed strategies, and assess the potential of a planned Phase 1b/2a program to advance the treatment of this difficult disease.

The KOLs
Dr. Peter Joel Hosein is a medical oncologist at the University of Miami's Sylvester Comprehensive Cancer Center, specializing in gastrointestinal cancers with a particular focus on pancreatic cancer. He leads an active clinical and translational research program investigating novel therapeutic combinations for PDAC, including immune-targeting and stroma-modulating approaches. Dr. Jashodeep Datta is a surgical oncologist at the University of Miami's Sylvester Comprehensive Cancer Center, specializing in gastrointestinal and hepatobiliary malignancies. His research focuses on the tumor immune microenvironment in pancreatic cancer and the development of novel immunotherapeutic strategies targeting tumor-promoting inflammatory pathways.

KOL Call details
Title: IL1RAP as a Therapeutic Target in Pancreatic Cancer: The Case for Nadunolimab
Date/Time: Monday, June 22^nd @ 11:00am ET (5:00pm CEST)
Webcasting Link: https://journey.ct.events/view/830dc882-cfc9-4405-8212-8b8eb3f92ff1
KOLs: Dr. Peter Joel Hosein & Dr. Jashodeep Datta

For further information, please contact
Hilde Steineger, CEO
Telephone: [phone]
E-mail: [e-mail]

Schreibe Deinen Kommentar